Neosoma Inc.
Advancing Brain Tumor Care and Clinical Trials
Est 2019
Advancing Brain Tumor Care and Clinical Trials
Published Jul 15, 2026
| Starting Price | Not publicly listed; vendor indicates pricing is based on MRI volume (vendor pricing statement) | Not publicly listed for enterprise; consumer-facing analysis services have different public price points | Not publicly listed; enterprise quotes typical |
| Best For | Neuro-oncology teams needing longitudinal lesion tracking and export to planning systems on a cloud platform | Sites using NeuroQuant for volumetrics wanting tumor/metastasis reporting within that ecosystem | Radiosurgery and neurosurgery workflows standardized on the Brainlab ecosystem |
| Key Strength | Neuro-oncology-focused features, lesion-level tracking, and FDA clearances for relevant indications | Broad neuroimaging footprint and established volumetric tools | Deep integration with radiosurgery planning workflows and automation for multi-target SRS |
| Key Weakness | Limited independent public reviews; opaque pricing; smaller vendor compared with some incumbents | Enterprise tumor workflow depth depends on modules purchased; distribution and procurement paths vary | Potential higher cost/complexity; optimized for Brainlab-centric workflows rather than PACS-centric longitudinal monitoring |
—
Where Neosoma appears to offer relevant capabilities:
Where competitors may hold advantages:
Independent market share data was not identified in public sources. Buyers should request references and proof of installations during due diligence.